Additionally, multitarget tyrosine kinase inhibitor (TKI) cabozantinib and AXL/c-MET selective inhibitor R428 both decreased AXL phosphorylation and TGFβ-induced E-cadherin expression (marker of EMT), cell viability, migration, and tumor growth in esophageal squamous cell carcinoma (ESCC) cells and xenograft models (78). This evidence concerns the gene CDH1 and esophageal squamous cell carcinoma.